MetaCap

NewAmsterdam Pharma Company N.V. (NAMS)

NASDAQ: NAMSHealth CareBiotechnology: Pharmaceutical PreparationsUSD

18.41-1.10 (-5.64%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NAMS stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$1.69
52-week range
17.90 – 42.21
Day range
18.29 – 19.78
Volume / Avg
1.74M / 1.66M
Beta
—

52-week range

$17.90$42.21

NAMS stock today

NewAmsterdam Pharma N.V. (NAMS) closed at $18.41 on Nov 20, down 5.64% (-$1.10), versus the S&P 500's 3.70% decline. Shares are 56.4% below their 52-week high of $42.21, set on May 11, 2026 and 2.8% above the 52-week low of $17.90, near the bottom of the past year's range. NAMS is down 47.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 51.9%.

NewAmsterdam Pharma N.V. has posted a net loss over the last twelve months (EPS of -$1.69), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About NewAmsterdam Pharma N.V.

Company profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Michael Harvey Davidson FACC, Facp., M.D.
Headquarters
Naarden
Employees
100

Financial highlights

Full financials

In fiscal 2025, NewAmsterdam Pharma N.V. generated $22.5 million in revenue, down 50.6% from fiscal 2024, its first annual decline since 2023. NewAmsterdam Pharma N.V. reported a net loss of $203.8 million, compared with a loss of $241.6 million a year earlier. Operating margin was -1002.9%.

NewAmsterdam Pharma N.V. annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$22.50M$45.56M$14.09M$102.69M—
Growth-50.61%+223.37%-86.28%——
Net income$-203.82M$-241.60M$-176.94M$-22.63M$-41.78M
EPS (diluted)$-1.72$-2.56$-2.15$-1.19$-3.81

Analyst forecast

Forecast

Consensus (16 analysts)

strong_buy

Avg. price target

$50.60+174.85%

  • Strong buy 3
  • Buy 12
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $37.38High $60.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.14 vs $-0.50
Surprise
+72.00%

NAMS news

All NAMS news

NewAmsterdam Pharma N.V. peers

Health Care sector
NAMS peer companies
CompanyPrice% ChgMarket capCompare
PRGOPerrigo Company plc15.94-0.62%$2.21Bvs NAMS
PHVSPharvaris N.V.31.28-1.20%$2.21Bvs NAMS
LKFTLakefront Biotherapeutics ADR33.31-0.24%$2.18Bvs NAMS
RCUSArcus Biosciences Inc.15.62-1.01%$2.25Bvs NAMS
HCMHUTCHMED (China) Limited ADR13.22-1.71%$2.30Bvs NAMS
PVLAPalvella Therapeutics Inc.142.85-2.00%$2.09Bvs NAMS
PBHPrestige Consumer Healthcare Inc.49.63+0.06%$2.35Bvs NAMS
AUPHAurinia Pharmaceuticals Inc14.70-1.28%$1.97Bvs NAMS

Indexes, lists and sector

NewAmsterdam Pharma N.V. stock FAQ

What is NewAmsterdam Pharma N.V.'s stock price today?

NAMS last traded at $18.41 as of Nov 20, 4:00 PM EST, down 5.64% on the day. Prices are delayed at least 15 minutes.

Who is NewAmsterdam Pharma N.V.'s CEO?

Dr. Michael Harvey Davidson FACC, Facp., M.D. is the chief executive officer of NewAmsterdam Pharma Company N.V., which has about 100 employees.

What is the NAMS 52-week high?

The 52-week high for NAMS is $42.21 and the 52-week low is $17.90. The stock is currently 56.4% below its high.

Compare NAMS